Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/96961
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDarbà, Josep-
dc.contributor.authorKaskens, Lisette-
dc.contributor.authorSorio Vilela, Francesc-
dc.contributor.authorLothgren, Mickael-
dc.date.accessioned2016-04-05T09:54:19Z-
dc.date.available2016-04-05T09:54:19Z-
dc.date.issued2015-02-
dc.identifier.issn1178-6981-
dc.identifier.urihttp://hdl.handle.net/2445/96961-
dc.description.abstractThe objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in Spain.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherDove Medical Press-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.2147/CEOR.S78349-
dc.relation.ispartofClinicoeconomics and Outcomes Research, 2015, vol. 2015, num. 7, p. 105-117-
dc.relation.urihttp://dx.doi.org/10.2147/CEOR.S78349-
dc.rightscc-by-nc (c) Darbà, Josep et al., 2015-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es-
dc.sourceArticles publicats en revistes (Economia)-
dc.subject.classificationAnàlisi cost-benefici-
dc.subject.classificationMenopausa-
dc.subject.classificationOsteoporosi-
dc.subject.otherCost effectiveness-
dc.subject.otherMenopause-
dc.subject.otherOsteoporosis-
dc.titleCost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec649914-
dc.date.updated2016-04-05T09:54:25Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid25709480-
Appears in Collections:Articles publicats en revistes (Economia)

Files in This Item:
File Description SizeFormat 
649914.pdf755.29 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons